Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.07

-0.06 (-0.18%)

, AGN

Allergan

$230.54

-7.41 (-3.11%)

08:12
10/13/16
10/13
08:12
10/13/16
08:12

British Court of Appeal rules against Pfizer in Lyrica patent case, Reuters says

The Court of Appeal in London endorsed an initial 2015 verdict that generic drugmakers, including Allergan (AGN), had not infringed Pfizer's (PFE) secondary patent for Lyrica related to its use as a treatment for pain, reported Reuters. Pfizer said it was "disappointed" by the ruling and would seek a further appeal, the report noted. Reference Link

PFE

Pfizer

$33.07

-0.06 (-0.18%)

AGN

Allergan

$230.54

-7.41 (-3.11%)

  • 01

    Nov

  • 06

    Nov

PFE Pfizer
$33.07

-0.06 (-0.18%)

08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
AGN Allergan
$230.54

-7.41 (-3.11%)

09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.
09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$366.48

-7.43 (-1.99%)

13:10
09/22/17
09/22
13:10
09/22/17
13:10
Options
Heavy trading in Tesla expiring options as the skid continues »

Heavy trading in Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

13:10
09/22/17
09/22
13:10
09/22/17
13:10
General news
Treasury Options Action: bullish call buying in block trade »

Treasury Options Action:…

13:07
09/22/17
09/22
13:07
09/22/17
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 9/22 Baker-Hughes…

RHHBY

Roche

$32.04

0.09 (0.28%)

13:07
09/22/17
09/22
13:07
09/22/17
13:07
Hot Stocks
Roche reports EU approval of Tecentriq in types of lung, bladder cancer »

Roche announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

JUNO

Juno Therapeutics

$41.62

-3.59 (-7.94%)

13:05
09/22/17
09/22
13:05
09/22/17
13:05
Options
Juno Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 22

    Sep

BHGE

Baker Hughes

$36.40

-0.18 (-0.49%)

13:04
09/22/17
09/22
13:04
09/22/17
13:04
Hot Stocks
Baker Hughes reports U.S. rig count down 1 to 935 rigs »

Baker Hughes reports the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 20

    Oct

NVLN

Novelion Therapeutics

13:03
09/22/17
09/22
13:03
09/22/17
13:03
Hot Stocks
Novelion unit Aegerion settles SEC fraud charges for $4.1M »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

, JWN

Nordstrom

$46.62

0.34 (0.73%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Periodicals
Dillard's mentioned in 'vague rumors' about attempting to go-private, Kass says »

Douglas Kass of TheStreet…

DDS

Dillard's

$55.07

-0.2189 (-0.40%)

JWN

Nordstrom

$46.62

0.34 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MMM

3M

$211.18

0.74 (0.35%)

13:02
09/22/17
09/22
13:02
09/22/17
13:02
Hot Stocks
3M files patent, trademark infringement lawsuit against Thunder Finish »

3M and 3M Innovative…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOSL

Fossil

$8.79

-0.21 (-2.33%)

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Options
Fossil put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/22/17
09/22
12:55
09/22/17
12:55
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

CMCSA

Comcast

$37.47

0.01 (0.03%)

, FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

12:53
09/22/17
09/22
12:53
09/22/17
12:53
Hot Stocks
Box Office Battle: 'Kingsman' sequel, 'LEGO: Ninjago' look to dethrone 'It' »

After two straight…

CMCSA

Comcast

$37.47

0.01 (0.03%)

FOX

21st Century Fox

$26.33

-0.05 (-0.19%)

VIAB

Viacom

$27.40

-0.32 (-1.15%)

SNE

Sony

$37.43

-0.035 (-0.09%)

DIS

Disney

$98.83

-0.06 (-0.06%)

CMCSK

Comcast

FOXA

21st Century Fox

$26.76

-0.11 (-0.41%)

VIA

Viacom

$38.20

-0.05 (-0.13%)

LGF.B

Lionsgate

$30.36

0.215 (0.71%)

TWX

Time Warner

$102.71

0.22 (0.21%)

LGF.A

Lionsgate

$31.57

0.32 (1.02%)

CBS

CBS

$58.85

0.06 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

  • 22

    Oct

  • 26

    Oct

  • 02

    Nov

AAPL

Apple

$153.39

-2.68 (-1.72%)

, FSLR

First Solar

$48.76

-0.09 (-0.18%)

12:51
09/22/17
09/22
12:51
09/22/17
12:51
General news
On The Fly: Top stock stories at midday »

Stocks on Wall Street…

AAPL

Apple

$153.39

-2.68 (-1.72%)

FSLR

First Solar

$48.76

-0.09 (-0.18%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

W

Wayfair

$75.24

-6.51 (-7.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DDC

Dominion Diamond

$14.19

0.005 (0.04%)

12:49
09/22/17
09/22
12:49
09/22/17
12:49
Hot Stocks
Dominion Diamond receives court approval for plan with The Washington Companies »

Dominion Diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

, VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

12:45
09/22/17
09/22
12:45
09/22/17
12:45
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week inflows…

SPY

SPDR S&P 500 ETF Trust

$249.20

-0.19 (-0.08%)

VOO

Vanguard S&P 500 ETF

$228.89

-0.18 (-0.08%)

XLF

Financial Select Sector

$25.43

-0.035 (-0.14%)

XLV

Health Care Select Sector SPDR

$81.25

-0.33 (-0.40%)

IWM

iShares Trust Russell 2000 Index Fund

$144.18

0.49 (0.34%)

GLD

SPDR Gold Trust

$123.09

0.41 (0.33%)

VWO

Vanguard FTSE Emerging Markets ETF

$44.17

-0.285 (-0.64%)

TLT

iShares 20+ Year Treasury Bond Fund

$125.84

-0.07 (-0.06%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.33

-0.01 (-0.01%)

IVV

iShares Core S&P 500

$252.18

-0.184 (-0.07%)

VO

Vanguard Mid-Cap Index Fund

$145.73

0.12 (0.08%)

VB

Vanguard Small-Cap Index Fund

$138.57

0.3 (0.22%)

VBK

Vanguard Small-Cap Growth Index Fund

$150.14

0.12 (0.08%)

MDY

SPDR S&P MidCap 400 ETF

$321.08

0.75 (0.23%)

SCHA

Schwab U.S. Small-Cap ETF

$65.69

0.19 (0.29%)

SVXY

ProShares Short VIX Short-Term Futures

$89.22

-0.5004 (-0.56%)

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$93.37

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
09/22/17
09/22
12:45
09/22/17
12:45
General news
Breaking General news story  »

Week of 9/22 Baker-Hughes…

ROK

Rockwell Automation

$177.39

0.06 (0.03%)

12:40
09/22/17
09/22
12:40
09/22/17
12:40
Options
Defensive option play opened in Rockwell »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.35

0.01 (0.01%)

12:30
09/22/17
09/22
12:30
09/22/17
12:30
Options
One week put buyer in the iShares High Yield Bond ETF »

One week put buyer in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$64.11

-0.89 (-1.37%)

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Options
Activision Blizzard call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
09/22/17
09/22
12:25
09/22/17
12:25
Conference/Events
FDIC to hold a teleconference »

The FDIC examination…

$NSD

NASDAQ Market Internals

12:17
09/22/17
09/22
12:17
09/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
09/22/17
09/22
12:16
09/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$144.20

0.51 (0.35%)

12:10
09/22/17
09/22
12:10
09/22/17
12:10
Options
300K puts trade in iShares Small Cap Fund driven by spread trades »

300K puts trade in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IP

International Paper

$55.69

-1.6 (-2.79%)

, WRK

WestRock

$55.41

-2.2 (-3.82%)

12:09
09/22/17
09/22
12:09
09/22/17
12:09
Recommendations
International Paper, WestRock, KapStone analyst commentary  »

International Paper…

IP

International Paper

$55.69

-1.6 (-2.79%)

WRK

WestRock

$55.41

-2.2 (-3.82%)

KS

KapStone

$21.62

-0.96 (-4.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$366.48

-7.43 (-1.99%)

, CSIQ

Canadian Solar

$15.86

-0.16 (-1.00%)

12:05
09/22/17
09/22
12:05
09/22/17
12:05
Hot Stocks
ITC finds injury to U.S. solar product makers, moves to remedy phase »

The U.S. International…

TSLA

Tesla

$366.48

-7.43 (-1.99%)

CSIQ

Canadian Solar

$15.86

-0.16 (-1.00%)

FSLR

First Solar

$48.76

-0.09 (-0.18%)

JASO

JA Solar

$7.85

-0.335 (-4.09%)

SUNEQ

SunEdison

$0.02

0.0005 (2.44%)

SPWR

SunPower

$7.37

-0.49 (-6.23%)

TSL

Trina Solar

YGE

Yingli Green Energy

$2.43

0.02 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.